Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 7Carcinoma, Non-Small-Cell Lung 5Parkinson Disease 4, Autosomal Dominant Lewy Body 3Lung Neoplasms 3Esophageal Neoplasms 3Neoplasms 2Neoplasm Metastasis 2Brain Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Solid Tumor, Adult 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Non-Small Cell Lung Cancer Metastatic 1Meningeal Neoplasms 1Melanoma 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer 1Endometrial Neoplasms 1

Interventions

pembrolizumab 4Proton Therapy 3toripalimab 1spartalizumab 1patritumab deruxtecan 1osimertinib 1mirdametinib 1leronlimab 1amivantamab 1Valganciclovir 1Radiotherapy 1Paclitaxel 1Lacteol 1Interleukin-2 1Docetaxel 1Carboplatin 1Blood Specimen Collection 1Bevacizumab 1BGB-283 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solid Tumor, Adult × patritumab deruxtecan × 1 year × Clear all
NCT06383884 2025-12-15

Patritumab Deruxtecan in Patients With Solid Tumor Harboring an NRG1 Fusion

Samsung Medical Center

Phase 2 Recruiting
30 enrolled
Other solid neoplasm

Solid Tumor, Adult

Data powered by HemOnc (CC BY 4.0) Colophon âš¡